Protein kinase Cι dictates tumor trajectory, cell plasticity, and immune surveillance in lung adenocarcinoma
Cell Reports · 2025
DOI: 10.1016/j.celrep.2025.116606 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2025. Verfasst von Duy T Nguyen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Ro…. Hauptthemen laut MEDLINE: Protein Kinase C, Adenocarcinoma of Lung, Lung Neoplasms, Immunologic Surveillance. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Florida Department of Health, National Institutes of Health National Cancer Institute.
Abstract (Originalsprache)
Lung adenocarcinoma (LUAD), the most prevalent form of lung cancer, is characterized by aggressive growth, immune resistance, and high tumor heterogeneity. Here, we demonstrate that genetic loss of protein kinase Cι (PKCι), which is found in ∼20% of LUAD patients, alters the trajectory of mouse Kras/Trp53-driven LUAD tumors from one resembling lung development to one mimicking lung regeneration. As a result, a major subset of tumor cells with PKCι loss exhibit cellular senescence and transcriptional similarities to the pre-AT1 transitional cell state (PATS) observed during alveolar regeneration after lung injury. Senescent PATS-like tumor cells inhibit cellular plasticity through stable proliferation arrest and induce formation of tertiary lymphoid structures (TLSs) that enhance anti-tumor immunity and patient responses to immune therapies. Importantly, human LUADs harboring genetic PKCι loss also contain TLSs and PATS-like tumor cells. Therefore, PKCι expression in mouse and human LUAD dictates tumor trajectory, cellular plasticity, and the immune microenvironment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
- Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA; Department of Pediatrics, Mayo Clinic, Rochester, MN, USA.
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, FL, USA.
- Department of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA.
- Department of Pediatrics, Mayo Clinic, Rochester, MN, USA.
Förderung
- NCI NIH HHS
- Florida Department of Health
- National Institutes of Health National Cancer Institute
- National Institutes of Health
- International Association for the Study of Lung Cancer
- Glenn Foundation for Medical Research
- Mayo Clinic Arizona
- Lung Cancer Research Foundation
Zitieren
APA
Nguyen, D. T., Prieto, L. I., Zhang, C., Li, H., Khoor, A., Weems, C., Jamieson, L., Jeganathan, K. B., Babu, S. R., Murray, N. R., Baker, D. J., & Fields, A. P. (2025). Protein kinase Cι dictates tumor trajectory, cell plasticity, and immune surveillance in lung adenocarcinoma. Cell Reports. https://doi.org/10.1016/j.celrep.2025.116606
Vancouver
Nguyen DT, Prieto LI, Zhang C, Li H, Khoor A, Weems C, et al. Protein kinase Cι dictates tumor trajectory, cell plasticity, and immune surveillance in lung adenocarcinoma. Cell Reports. 2025. doi:10.1016/j.celrep.2025.116606
BibTeX
@article{Nguyen2025,
author = {Nguyen, Duy T and Prieto, Luis I and Zhang, Cheng and Li, Hu and Khoor, Andras and Weems, Capella and Jamieson, Lee and Jeganathan, Karthik B and Babu, Srinidhi R and Murray, Nicole R and Baker, Darren J and Fields, Alan P},
title = {Protein kinase Cι dictates tumor trajectory, cell plasticity, and immune surveillance in lung adenocarcinoma},
journal = {Cell Reports},
year = {2025},
doi = {10.1016/j.celrep.2025.116606}
}
EUVIMED